StockIQStockIQ.tech

Cigna Group (CI) Stock Analysis

--

Free AI-powered analysis and research for Cigna Group stock

Sector: Healthcare

CI snapshot

Data as of 3 Nov 2026 close. Updated daily.

Last close
295.32 USD (+0.04%)
52-week range
239.51 – 316.27
Position in range
73%
1-year change
+14.2%
Market cap (USD)
$78.0B
P/E (trailing)
12.3
RSI (14-day)
53
vs 200-day average
+4.8%
MACD
Below signal line
StockIQ score: 53/100 · Mixed signals

Cigna Group scores 53/100 on StockIQ's model, which reads as mixed signals overall. The price is above its 200-day average and at 73% of its 52-week range, up 14.2% over the past year. Latest reported figures show a profit margin of 2.3%, return on equity of 16.8% and revenue growth of +6.7%.

What is driving the score
  • RSI Neutral: +5
  • Uptrend: +5
  • MACD Bearish: -8
  • Low P/E (12.3): +10
  • Weak Profit Margin (2.3%): -8
  • Low Liquidity (0.85 Current Ratio): -10
  • Strong ROE (16.8%): +5
  • Above MA200: +4
  • Up Over 1 Year (+14.2%): +3
  • Low Volume (0.3x): -3

Automated, general information only – not financial advice. Scores can be wrong. How the score works

Full CI report

Cigna Group (CI) is listed in the Healthcare sector. The snapshot on this page updates daily; run a full report for the complete breakdown.

Analyze CI Now β†’

πŸ“° Latest Update

What Analyst Projections for Key Metrics Reveal About Cigna (CI) Q3 Earnings

Analysts project Cigna (CI) will report Q3 earnings of $7.46 per share, reflecting a 4.7% year-over-year decline, with revenues expected to reach $73.53 billion, a 5.7% increase from the previous year. Key metrics indicate growth in various segments, including Evernorth Health Services and Cigna Healthcare premiums, while the Medical Care Ratio is estimated at 85.1%. Cigna's shares have risen 10.2% over the past month, outperforming the S&P 500's decline of 0.9%.

Read full article β†’

History

People also watch

REGN
Regeneron Pharmaceuticals Inc.
--
JNJ
Johnson & Johnson
--
LLY
Eli Lilly and Company
--
VTRS
Viatris Inc.
--
AMPH
Amphastar Pharmaceuticals, Inc.
--